Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

nties, particularly those inherent in the process of developing and commercializing drugs. Alexza's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in Alexza's Annual Report on Form 10-K for the year ended December 31, 2008, and Alexza's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "If our product candidates fail to show a clinically significant benefit compared to placebo, they will not be approved for marketing" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... -- Decision Resources Group finds that the laparoscopic device market ... increase to a value of over $4.3 billion by ... the large direct energy device market. In particular, premium-priced ... to the advantages they offer and as new products ... Resources Group,s coverage of the U.S. laparoscopic device market: ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: ... healthcare products and services in the People,s Republic of ... financial results for the three and nine-month periods ended ... the market closes. Management will host a conference call ...
... March 4, 2011 A group of Canadian researchers led ... Osteoarthritis Research Unit at the University of ... trial in which they confirm, for the ... (qMRI), the disease modifying effects of chondroitin sulphate, a symptomatic ...
Cached Medicine Technology:Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 2The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis Has Been Confirmed by MRI 3
(Date:12/21/2014)... December 22, 2014 BellasDress.com offers a ... for women. Today, it announces its BellasDress Christmas ... at its online store. , BellasDress is a famous ... to its fans through a series of promotions. The ... every customer. , “We are proud of offering ...
(Date:12/21/2014)... new collection of 2015 spring wedding dresses was released ... in this collection, and all of them are designed ... promises to provide the most fashionable designs to its ... trends come and go. If ladies have any questions ... ready to assist. , “These new models can ...
(Date:12/21/2014)... 21, 2014 Recently, one of the ... LunaDress Prom Shop has introduced its new collection ... offering big discounts on all its prom dresses &amp; ... LunaDress insists on providing top quality dress products and ... is considered as one of the best prom dresses ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage Rock ... the Doors International Ballroom at the Hilton Hotel in ... only time that Morrison's mother would see her son ... According to Hawley, “This would be the Doors only ... Roller Rink earlier that year and would return to ...
(Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... prescription drug cards now available to older Americans offer ... which are marketed by private companies, charge seniors a ... exchange for discounts. But savings are minimal for many ... average, seniors in three large cities -- Washington, Chicago ...
... model that mimics two human hereditary dental defects-dentinogenesis ... Kulkarni and his colleagues genetically// engineered mice that ... beta-1) in their teeth. The animals were born ... their teeth became discolored and eventually fractured, leaving ...
... more or less than seven hours a night have increased ... over a six year time period// shows that the old ... need modifying. Looking at the length of time people sleep ... of Texas, and colleagues, find that seven hours is the ...
... no longer an exclusively Western problem. Researchers say ... to people in developing nations, particularly children. Until ... biggest threats to the health of poor people ... technology, food processing and even leisure time in ...
... The incidence of kidney cancer in the UK has risen by ... almost 6,000 people a year. Research in UK says that 5,700 ... are among the lowest in Europe.// The disease accounts for an ... the UK. ,According to Dr Nick James, a consultant at ...
... to conduct tests for any Indian doctor having graduated abroad ... a higher standards amongst doctors, the government has made it ... said today. , The new ... that students who want to enrol in MBBS course abroad ...
Cached Medicine News:Health News:Heriditary dental disorders 2
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: